217 related articles for article (PubMed ID: 34448414)
21. Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab.
Keen JA; Correa T; Pham C; Claussen AD; Hansen MR; Carter KD; Shriver EM
Ophthalmology; 2024 Jan; 131(1):30-36. PubMed ID: 37567417
[TBL] [Abstract][Full Text] [Related]
22. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
Smith TJ
J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
[TBL] [Abstract][Full Text] [Related]
23. Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
[TBL] [Abstract][Full Text] [Related]
24. Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic.
Yee MD; McCarthy J; Quinn B; Surani A
WMJ; 2023 May; 122(2):134-137. PubMed ID: 37141481
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
[TBL] [Abstract][Full Text] [Related]
26. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
Kossler AL; Douglas R; Dosiou C
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
[TBL] [Abstract][Full Text] [Related]
27. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
Hoang TD; Nguyen NT; Chou E; Shakir MK
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
[TBL] [Abstract][Full Text] [Related]
28. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
[TBL] [Abstract][Full Text] [Related]
29. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
Ugradar S; Kossler AL; Douglas R; Cockerham K
J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
[TBL] [Abstract][Full Text] [Related]
30. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
[TBL] [Abstract][Full Text] [Related]
31. Novel teprotumumab treatment of severe thyroid dermopathy; ototoxicity as an adverse side effect.
Patel RT; Grider DJ; Ramey N
Dermatol Online J; 2023 Feb; 29(1):. PubMed ID: 37040908
[TBL] [Abstract][Full Text] [Related]
32. Treating Thyroid Associated Ophthalmopathy in Pediatric Patients.
Dong T; Fu Z; Wang X
Front Endocrinol (Lausanne); 2022; 13():900204. PubMed ID: 35837312
[TBL] [Abstract][Full Text] [Related]
33. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
Ali F; Chorsiya A; Anjum V; Ali A
Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
[TBL] [Abstract][Full Text] [Related]
34. Audiology findings in patients with teprotumumab associated otologic symptoms.
Yu CY; Correa T; Simmons BA; Hansen MR; Shriver EM
Am J Ophthalmol Case Rep; 2021 Dec; 24():101202. PubMed ID: 34585021
[TBL] [Abstract][Full Text] [Related]
35. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
[TBL] [Abstract][Full Text] [Related]
36. A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease.
Douglas RS; Parunakian E; Tolentino J; Malkhasyan E; Geng J; Sherman M; Ugradar S
Thyroid; 2024 Jan; 34(1):134-137. PubMed ID: 37962269
[No Abstract] [Full Text] [Related]
37. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
[TBL] [Abstract][Full Text] [Related]
38. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient.
Chen KW; Phelps PO
Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764
[TBL] [Abstract][Full Text] [Related]
39. New-Onset of Inflammatory Bowel Disease in a Patient Treated With Teprotumumab for Thyroid Associated Ophthalmopathy.
Ashraf DC; Jankovic I; El-Nachef N; Winn BJ; Kim GE; Kersten RC
Ophthalmic Plast Reconstr Surg; 2021 Sep-Oct 01; 37(5):e160-e164. PubMed ID: 33710035
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
